Cargando…
Ubiquitin and SUMO conjugation as biomarkers of acute myeloid leukemias response to chemotherapies
Ubiquitin and the ubiquitin-like SUMO are covalently conjugated to thousands of proteins to modulate their function and fate. Many of the enzymes involved in their conjugation are dysregulated in cancers and involved in cancer cell response to therapies. We describe here the identification of biomar...
Autores principales: | Gâtel, Pierre, Brockly, Frédérique, Reynes, Christelle, Pastore, Manuela, Hicheri, Yosr, Cartron, Guillaume, Piechaczyk, Marc, Bossis, Guillaume |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Life Science Alliance LLC
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7167290/ https://www.ncbi.nlm.nih.gov/pubmed/32303586 http://dx.doi.org/10.26508/lsa.201900577 |
Ejemplares similares
-
The SUMO Pathway in Hematomalignancies and Their Response to Therapies
por: Boulanger, Mathias, et al.
Publicado: (2019) -
The NADPH oxidase NOX2 is a marker of adverse prognosis involved in chemoresistance of acute myeloid leukemias
por: Paolillo, Rosa, et al.
Publicado: (2022) -
SUMO and Transcriptional Regulation: The Lessons of Large-Scale Proteomic, Modifomic and Genomic Studies
por: Boulanger, Mathias, et al.
Publicado: (2021) -
DeSUMOylation of chromatin-bound proteins limits the rapid transcriptional reprogramming induced by daunorubicin in acute myeloid leukemias
por: Boulanger, Mathias, et al.
Publicado: (2023) -
SUMO: regulating the regulator
por: Bossis, Guillaume, et al.
Publicado: (2006)